COMMUNIQUÉS West-GlobeNewswire

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
14/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its [...]
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
14/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to [...]
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025
14/11/2025
COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for [...]
Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis
14/11/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis Les financements [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
14/11/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 nov. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
14/11/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 14, 2025 (GLOBE NEWSWIRE [...]
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens
14/11/2025
Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational Phase 2b trial, [...]
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
13/11/2025
Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end Recent data presented at [...]
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
13/11/2025
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far. In Cohort 6, [...]
Aptose Reports Third Quarter 2025 Results
13/11/2025
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 [...]
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
13/11/2025
13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S Copenhagen, Denmark, 13 November 2025, (GLOBE NEWSWIRE [...]
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
13/11/2025
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re- [...]
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
13/11/2025
Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise [...]
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
14/11/2025
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
14/11/2025
INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments [...]
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
14/11/2025
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning [...]
Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
13/11/2025
Conference call today, November 13, 2025, at 4:30 PM ET SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025 [...]
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
13/11/2025
~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results [...]
Amneal Receives U.S. FDA Approval for Iohexol Injection
13/11/2025
First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. [...]

Pages